（by Jennifer Jiang, Chief Attorney of Bilingual Lawyers)

According to China Security Ministry, GlaxoSmithKline executives in China have confessed to bribery and tax violations. The case against Britain's biggest drugmaker involved a large number of staff and a huge sum of money over an extended period of time, with bribes offered to Chinese government officials, medical associations, hospitals and doctors to boost sales and prices. GlaxoSmithKline Plc (GSK) executives also used fake receipts in unspecified tax law violations.


By Bilingual Lawyers: Quite a few international companies (Lucent Technologies, Siemens, IBM, Biomet, Pfizer, etc.) have been fined by the Securities and Exchange Commission and Department of Justice in the United States for corruption in China against Foreign Corrupt Practices Act; however, China authorities seldom put fines on those companies, less to say the investigation on criminal level before. The GSK case tells foreign companies it’s time to pay great attention to China commercial bribery laws.

The definition of commercial bribery and legal consequences can be found through the Chinese pages of our website.